← Leaderboards
Judith Karp
University Of Maryland Baltimore
$813,236
Attributed
$813,236
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$813,236 · 5
By mechanism
U01$723,903 · 1
M01$89,333 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantComputer Retrieval Of Information On Scientific Projects DatabaseUnited States National Institutes Of HealthInstitutionFundingCytotoxicityResourcesAcute LeukemiaSourceResearch PersonnelHuman SubjectHuman Therapy EvaluationGender DifferenceDrug MetabolismColony Stimulating FactorDrug Screening /EvaluationAntineoplasticsButyratesApoptosisAdultClinical Trial Phase IClinical ResearchCarboplatinCell Differentiation
Grant awards (7)
A PHASE I/II STUDY OF FLAVOPIRIDOL FOR ADULTS WITH LEUKEMIAS$62,554
M01 · FY2007 · RR · contact PI
PHASE II TRIAL OF TRIAPINE$10,127
M01 · FY2007 · RR · contact PI
ORAL ETOPOSIDE IN COMBINATION WITH FARNESYLTRANSFERASE INHIBITOR R115777$8,663
M01 · FY2007 · RR · contact PI
TRIAL OF 17-AAG AND CYTARABINE IN LEUKEMIA AND MYELODSPLASTIC SYNDROME$7,989
M01 · FY2007 · RR · contact PI
PHASE I TRIALS OF ANTICANCER AGENTS$391,225
U01 · FY2001 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$268,522
U01 · FY2000 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$64,156
U01 · FY2000 · CA